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Li-Fraumeni Syndrome (LFS) is a hereditary cancer syndrome which predisposes 
individuals to cancer beginning in childhood.  These risks are spread across a 
lifetime, from early childhood to adulthood. Mutations in the p53 tumor suppressor 
gene are known to cause the majority of cases of LFS. The risk for early onset 
cancer in individuals with Li-Fraumeni Syndrome is high. Studies have shown that 
individuals with LFS have a 90% lifetime cancer risk. Children under 18 have up to a 
15% chance of cancer development. Effectiveness of cancer screening and 
management in individuals with Li-Fraumeni Syndrome is unclear. Screening for 
LFS-associated cancers has not been shown to reduce mortality. Due to the lack 
of effective screening techniques for childhood cancers, institutions vary with 
regard to their policies on testing children for LFS.  There are currently no national 
guidelines regarding predictive testing of children who are at risk of inheriting LFS. 
No studies have looked at parental attitudes towards predictive p53 genetic 
testing in their children. This was a cross-sectional pilot study aimed at describing 
these attitudes. We identified individuals whose children were at risk for inheriting 
p53 genetic mutations. These individuals were provided with surveys which 
included validated measures addressing attitudes  and beliefs towards genetic 
testing. The questionnaire included qualitative and quantitative measures. Six 
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individuals completed and returned the questionnaire with a response rate of 
28.57%. In general, respondents agreed that parents should have the opportunity 
to obtain p53 genetic testing for their child. Parents vary in regard to their attitudes 
towards who should be involved in the decision making process and at what time 
and under what considerations testing should occur. Testing motivations cited 
most important by respondents included family history, planning for the future and 
health management. Concern for insurance genetic discrimination was cited as 
the most important “con” to genetic testing. Although limited by a poor response 
rate, this study can give health care practitioners insight into testing attitudes and 
beliefs of families considering pediatric genetic testing.  
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Background 
 Li-Fraumeni Syndrome (LFS) is a hereditary cancer predisposition 
syndrome which predisposes individuals to a large range of cancers beginning 
in childhood. Individuals with LFS have up to a ninety percent lifetime risk of 
developing cancer. Originally discovered through bedside clinical 
observations and epidemiological studies, LFS has an estimated birth 
prevalence of 1 in 5,000 (Lalloo, Varley, Ellis, O’Dair & Pharoah, 2003).   
In the general population, cancer was the second leading cause of 
death in 2006, preceded by heart disease (American Cancer Society, ACS, 
2009). Men have a one in two lifetime cancer risk, while a woman’s lifetime 
risk is one in three (ACS, 2009). These risks increase exponentially with age. 
Most cancers occur sporadically throughout a person’s life-time, however, 
five to ten percent of cancers can be attributed to a hereditary cause 
(Schneider, 2002).  
Greater than 200 hereditary cancer predisposition syndromes have 
been identified (Schneider, 2002). As a group, hereditary cancer syndromes 
confer an increased risk to individuals of developing certain cancer types in 
their lifetime, often at younger ages than the general population. Individuals 
with hereditary cancer syndromes often have a significant family history of 
cancer with multiple generations and individuals affected with cancer. 
Sometimes these individuals will have a personal or family history of a rare 
cancer type such as male breast cancer, ovarian cancer or adrenocortical 
carcinoma. It is crucial to recognize these syndromes in an individual as there 
are established guidelines in regard to management, prevention and treatment 
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for most hereditary cancer syndromes. Once an individual has been identified 
to have a hereditary cancer syndrome, it is important to notify other at risk 
relatives and facilitate testing. It is often helpful for these individuals to meet 
with a professional such as a physician or a genetic counselor to facilitate 
education and testing (Schneider, 2002).  
Established guidelines have been created regarding testing 
individuals for several hereditary cancer syndromes. The main theme in these 
guidelines is a risk/benefit analysis. In general, if the benefit of testing will 
not manifest until adulthood, genetic testing is postponed until the age of 18 
(American College of Medical Genetics (ACMG) & American Society of 
Human Genetics (ASHG), 1995). Hereditary cancer syndromes, such as Li-
Fraumeni syndrome, that confer a cancer risk in childhood but have no 
established management, are more controversial. Testing for cancer 
syndromes such as LFS is often at the discretion of the physician facilitating 
the testing since there is currently a lack of guidelines regarding when to test 
an individual for these conditions. It is also unclear what kind of management 
should be implemented in hereditary cancer syndromes like LFS. The 
American Society of Clinical Oncology (ASCO) recommends that physicians 
and parents participate together in the decision making process (ASCO, 
2003). Few studies have examined the interest parents have regarding having 
their minor-aged child tested for a hereditary cancer syndrome in which 
management in childhood is limited (Patenaude, Basili, Fairclough & Li, 
1996). In 1969, Li and Fraumeni reported four families who appeared to have 
autosomally dominant inherited cancers, including childhood cancers, soft 
13 
 
tissue sarcomas and breast cancer. This collection of cancers was termed Li-
Fraumeni Syndrome, after the investigators who initially described it. In 
1988, Li and Fraumeni searched the Cancer Family Registry of the National 
Cancer Institute. They discovered twenty four individual families who had a 
similar pattern of cancers.  From this study, it became apparent that 
individuals with Li-Fraumeni Syndrome had increased risks for brain tumors, 
leukemia, breast cancer and adrenal cortical tumors. The researchers noted 
that these cancers typically occurred before the age of 50 (Li et al., 1996).    
 Meanwhile, in 1978, Lynch observed several families with 
apparent hereditary segregation of cancer which was consistent with Li-
Fraumeni Syndrome.  He too noted that these families had a predominance of 
sarcoma, breast cancer, leukemia and adrenal cortical tumors.  Lynch referred 
to the collection of these specific cancers in one family as SBLA syndrome 
(sarcoma, breast/brain, leukemia/laryngeal/lung cancer and adrenal cortical 
carcinoma). A genetic segregation pattern was established for this hereditary 
pattern of cancers which was compatible with autosomal dominant 
inheritance. The study concluded that the reported kindred had a rare, 
deleterious autosomal dominant aggregation of cancers (Lynch, Mulcahy, 
Harris, Guirgis & Lynch, 1978). This mode of inheritance was then confirmed 
by segregation analysis of 159 childhood soft tissue sarcoma patients in 1992 
(Lustbader, Williams, Bondy, Strom & Strong, 1969). 
The gene responsible for Li-Fraumeni Syndrome was discovered in 
1990 (Malkin et al., 1990). Linkage analysis was not possible due to the rarity 
of Li-Fraumeni Syndrome and its deleterious nature. Therefore, a candidate 
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gene approach was taken. Investigators were interested in p53 because of the 
gene’s known involvement in the tumorigenesis of many sporadic cancers (it 
is estimated that p53 is mutated in fifty percent of all sporadic tumors) 
(Levine, 1997). In 1990, five families with LFS were analyzed. All of these 
kindreds were found to have p53 mutations (Malkin et al., 1990). Soon, 
another family which fit clinical criteria for LFS was tested. Several members 
in this family tested positive for a mutation in p53 (Srivastave, Zou, Pirollo, 
Blattner & Chang, 1990).  
P53 is a tumor suppressor gene that is commonly mutated in 
sporadic cancers. Termed “the guardian of the genome”, p53 is key in cell 
cycle regulation (Lane, 1992). It has several functions including activation of 
DNA repair, arresting the cell cycle and initiating apoptosis (Lane, 1992). 
This explains why individuals with a germ line p53 mutation have a 
significantly increased cancer risk. Tumor formation in individuals with p53 
mutations is most often consistent with Knudson’s “two-hit” hypothesis, in 
which cancer develops in individuals that inherit the “first hit” or mutation 
and cancer occurs in cells that acquire a “second hit” or mutation (Levine, 
1996)(Knudson, 1971).  Therefore, it is important for individuals with a germ 
line p53 mutation to avoid oncogenic environmental factors such as radiation.  
Initially, it was thought that germ line mutations in another gene, 
CHEK2, could account for other cases of LFS. Lee et al. (2001) and Varley 
(2003) reported on several families with germ line CHEK2 mutations who 
satisfied the LFS clinical criteria (Lee et al., 2001) (Varley,2003). Currently, 
CHEK2 mutations are generally not considered a part of Li-Fraumeni 
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Syndrome. Rather, they are thought to be low penetrant tumor suppressor 
genes involved in breast cancer (Vahteristo et al., 2002).  
Li-Fraumeni Syndrome is an autosomal dominant and highly 
penetrant hereditary cancer syndrome. Greater than seventy percent of 
individuals with Li-Fraumeni Syndrome have a p53 germ line mutation 
(Chompret, 2000). Mutations in the p53 tumor suppressor gene are known to 
cause the majority of cases of LFS (Malkin, 1994). Commercial molecular 
testing consists of direct sequencing of the p53 coding region, the first non-
coding exon , promoter, all splice site junctions, and  the 3’-untranslated 
region, rearrangement and large duplication/deletion testing (Varley, 2003).  
Unlike other cancer susceptibility syndromes, which may predispose 
individuals to site-specific tumors, LFS increases an individual’s risk of 
developing a variety of tumor types (Hartley, Birch, Kelsey, Marsden, Harris 
and Teare, 1989) (Varley, 2003). The malignancies which dominate this 
condition include soft tissue sarcoma, osteosarcoma, brain tumors, adrenal 
cortical carcinoma and premenopausal breast cancer. Additional data suggests 
that Li-Fraumeni Syndrome may also be associated with other diverse 
neoplasms including pancreatic cancer, leukemia, Wilms’ tumor and 
neuroblastoma(Li et al., 1988) (Birch et al., 2001) (Nichols, Malkin, Garber, 
Fraumeni and Li, 2001). Other cancers have been seen in individuals with Li-
Fraumeni Syndrome including renal, gonadal germ cell, melanoma, colon, 
ovarian and lung cancer (Nichols et al., 2001) (Bougeard et al., 2008).   
Individuals with LFS are clearly predisposed to tumor formation in a large 
range of tissues and tissue types.  
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LFS increases an individual’s risk of developing multiple primary 
tumors.  These risks are spread across a lifetime, from early childhood to 
adulthood, and the risk for early onset cancer in individuals with Li-Fraumeni 
Syndrome is high.  In 2000, Chompret et al. found that individuals with Li-
Fraumeni Syndrome have a 15% chance of developing cancer from ages 0 to 
15 and a 54% chance of developing cancer between ages 16 to 45 years.  
Overall, the individuals in this study had up to a 68% lifetime risk of 
developing cancer (Chompret et al., 2000). Bihan et al. (1995) studied five 
individuals with p53 mutations and estimated age specific cancer risks. They 
found that the risk for cancer was 42% in individuals aged 0 to 16, 38% in 
individuals aged 17 to 45, and above 63% for individuals aged 45 and older.  
Using segregation analysis, Lustbader et al. (1992) found that individuals 
with Li-Fraumeni Syndrome had up to a 50% risk of cancer development by 
age forty, and a 90% lifetime cancer risk (by age 60). By age thirty, nearly 
50% of individuals with LFS will develop cancer, in comparison to only one 
percent of the general population (Malkin et al., 1990). By age seventy, over 
ninety percent of individuals with a germ line p53 mutation will develop a 
malignancy (Malkin et al., 1990).   
Cancer screening and management in individuals with Li-Fraumeni 
Syndrome is not well defined. Screening for LFS-associated cancers, 
however, has not been shown to reduce mortality (Varley, Evans & Birch, 
1997). No proven beneficial methods for childhood cancers currently exist. 
Methods that may be used to detect childhood cancers include blood cell 
counts and radiographic studies, the predictive power of these tests is not 
17 
 
known. Magnetic resonance imaging (MRI) may be used to scan for 
cancerous lesions. MRI is desirable because it can detect small lesions 
without delivering radiation the body. This is important because individuals 
with LFS are especially sensitive to radiation, which can potentiate tumor 
development. Unfortunately, MRI is a costly procedure and may not be 
available to all affected individuals (Varley et al., 1997).  
Screening recommendations regarding LFS have been published 
(National Comprehensive Cancer Network, NCCN, 2010) Screening for 
children includes annual and thorough physicals,. Based on family history, 
other forms of organ-targeted surveillance should be implemented. It is 
important to keep in mind, however, that these screening methods have not 
been proven to be effective. Screening for adults with LFS includes annual 
physicals, dermatology evaluations. Women with LFS should have a clinical 
breast exam biannually beginning at 20-25. They should rotate screening 
methods between mammograms and breast MRI. All individuals with Li-
Fraumeni Syndrome should consider colorectal cancer screening beginning at 
age 20-25, with subsequent colonoscopies every two to five years. Again, 
organ targeted surveillance should be practiced based on family history of 
specific tumors (Varley, 1997) (Evans et al.,1997) (NCCN, 2010). 
The use of MRI and PET (position emission tomography) scans in 
screening for LFS-related tumors is controversial. Clinicians are inconsistent 
in their attitudes towards the use of this technology in monitoring individuals 
for cancer. Proponents of the method believe that it will detect lesions that are 
otherwise undetectable.  Others argue that it will subject the patient to many 
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unnecessary biopsies and procedures (Wertz, Fanos & Reilly, 1994) (Varley 
et al., 1997) (Goyen & Debatin, 2006). 
Management and screening in individuals with LFS is a complicated 
process since LFS is associated with a wide variety of tumors in several organ 
systems. Several of the LFS associated cancers are difficult to detect until late 
stages of its growth, and the later a cancer is detected, the poorer the 
prognosis. Most importantly, individuals with LFS must be alert to changes in 
their health and seek medical attention if they experience any symptoms 
(Wertz, et al., 1994) (Varley, 2003) (Evans et al., 1997).    
Due to the lack of appropriate screening techniques for childhood 
cancers, institutions vary with regard to their policies on testing children for 
Li-Fraumeni Syndrome. An international consortium of physicians and 
researchers met in 1992 to develop a consensus towards management of and 
testing individuals for LFS, and this meeting concluded that genetic testing 
should not be offered to minors who are at risk of inheriting LFS. There has 
been no follow-up in the last seventeen years to these recommendations (Li et 
al., 1992)  
 Before the molecular cause of Li-Fraumeni Syndrome was 
discovered, diagnosis was made on the basis of clinical criteria. Three criteria 
guidelines exist for the diagnosis of Li-Fraumeni Syndrome.  
 A person who is diagnosed with LFS based on the classic or 
original criteria must meet all three of the following:  
1.  A proband with a sarcoma diagnosed before the age of 45 
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2. A first degree relative with any cancer under the age of 45 
3. A  first or second degree relative with any cancer under the age 
of 45 or a sarcoma at any age (Li & Fraumeni, 1969) 
Following the creation of these criteria, a new set of guidelines was 
set forth by Chompret et al. to diagnose individuals with LFS. These criteria 
are less dependent on family history of cancer and focused more on an 
individual’s personal history. An individual who has a clinical diagnosis of 
LFS based on the Chompret criteria must meet one of the following: 
1.  A proband with a tumor belonging to the LFS spectrum (soft 
tissue sarcoma, osteosarcoma, brain tumor, premenopausal 
breast cancer. Adrenal cortical carcinoma, leukemia, lung, 
bronchoalveolar cancer) prior to the age of 46 years AND at 
least one first or second degree relative with a LFS tumor 
(excluding breast cancer if the proband has breast cancer) 
2. A proband with multiple tumors (except multiple breast tumors). 
Two of which belong to the LFS tumor spectrum and the first 
tumor occurred before age 46 
3. A proband with adrenocortical carcinoma or choroid plexus 
tumor, irrespective of family history (Chompret, 2002) 
Currently, Li-Fraumeni Syndrome is diagnosed in two ways: 
clinically and molecularly. While historically individuals with Li-Fraumeni 
syndrome were only given a clinical diagnosis, we now have the possibility to 
perform genetic testing on individuals for molecular confirmation. 
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Additionally, individuals who are at risk of inheriting LFS can have 
predictive genetic testing based on the identified p53 mutation in the family.  
Molecular testing of the p53 gene is now routinely performed to 
facilitate the diagnostic process of LFS. Seventy percent of individuals who 
fit the clinical description of LFS will have a mutation in the p53 gene, and 
sequencing of the entire gene will detect ninety-five percent of p53 mutations 
in these individuals (Birch et al., 1994) (Varley, 2003)(Bougeard et al., 2008). 
The remaining five percent will have a deletion, rearrangement, or 
unidentified mutation in the p53 gene (Nichols et al., 2001). Between 7 to 
20%  of p53 mutations are believed to be de novo events (Gonzalez et al., 
2009).  
With new technology come new questions. Issues among debate in 
the genetics community involve who should be tested for LFS and at what 
age should testing occur (Li et al.,1992). When these questions are 
considered, several things must be taken into account. What benefit would 
genetic testing results have on the patient? At what age do cancer risks begin, 
and are there affective approaches to manage these risks? These questions are 
not specific to Li-Fraumeni syndrome and can be applied to all cancer 
syndromes in general. Several agencies have set forth recommendations and 
guidelines to help health professionals answer these difficult questions.  
The American Society of Clinical Oncology (ASCO) published 
recommendations regarding testing children for cancer susceptibility in 
general. ASCO recommends that one should consider several variables when 
deciding to offer testing to a potentially affected child.  First, the child must 
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be at risk for a pediatric cancer. Also, the test under consideration should be 
adequately interpretable, and the test results and implications should be clear 
to the ordering clinician. Test results should be used for diagnosis, or 
influence the medical management of the child, and evidence based risk 
reduction strategies should be available (ASCO, 2003). Conditions such as 
Multiple Endocrine Neoplasia (MEN) and Familial Adenomatous Polyposis 
(FAP) have appropriate childhood interventions for their associated cancers 
(Brandi et al., 2001) (Rozen and  Macrael, 2006 ). Because of this, testing in 
children at risk for these conditions is appropriate. Testing for the adult onset 
cancer susceptibility syndromes such as Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC) and Lynch Syndrome (HNPCC) is typically not 
recommended in minors since the benefit that individuals could derive from 
these tests would not accrue until adulthood. ASCO enforces the belief that 
the parents or guardian of the child should have the authority to decide 
whether or not to test (ASCO, 2003).  
The American Society of Human Genetics (ASHG) and the 
American College of Medical Genetics (ACMG) published literature 
regarding ethical, legal and psychosocial implications surrounding genetic 
testing in minors (1995). In addition to emphasizing the necessity for a timely 
medical benefit to the child, these guidelines focus on the need for genetic 
testing to contribute to the global well-being of the child. Individuals 
undergoing genetic testing may experience anxiety, altered self- image, and 
uncertainty. ASHG and ACMG suggest that if the psychological or medical 
benefits of testing won’t occur in childhood, testing should be postponed until 
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the child is old enough to make an autonomous competent decision. If the 
balance of benefits and harms related to pediatric genetic testing is unclear, 
ASHG and ACMG recommend that the provider respect the wishes and 
decisions of the family, after adequate counseling. In the event that testing is 
clearly harmful in the child, providers are encouraged to advocate for the best 
interest of that child (ACMG/ASHG, 1995).   
Upon reviewing national agency guidelines regarding predictive 
testing in minors, one frequently encounters the concept of “best interest”. 
For a genetic test to be justified, it must be in the best interest of the child, 
both medically and psychologically. One key tenet in all genetic testing is 
informed consent. Testing minors can be especially sensitive because a 
minor’s informed consent cannot be given. Instead, it is up to the parent or 
legal guardian to make medical decisions for the child. It is expected that 
parents know their children better than health care providers and are therefore 
in the unique position to determine what is in the best interest of their child 
(Wertz et al., 1994). 
As children mature, they are often included in the health care 
decision making process. The older a child gets, the more likely they are to 
grasp the intellectual concepts that are key in making these decisions. They 
are also likely to have increased psychosocial skills as they get older. It is 
generally accepted that “as soon as children are able to communicate and 
participate in decisions that affect them, they should be encouraged to 
participate in all aspects of the decision making process” (Borry, 2009). It is 
therefore important to involve children as well as their guardians in 
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counseling and information giving sessions. It would be reasonable for 
parents to defer genetic testing until their child is old enough to have active 
participation in the decision.  
Multiple issues arise when considering genetic testing in minors. 
Test results may impact several areas of an individual’s life including 
decision making, reproductive decisions, education, occupation, insurance 
coverage and overall lifestyle. Genetic test results may impact family 
dynamic or impose guilt or anxiety on family members (ACMG/ASHG, 
1995). Testing in minors denies the rights of these individuals to make an 
autonomous decision to be tested when they reach adulthood. Individuals lose 
confidentiality of results from family members when they are tested as minors 
(Andrews et al., 2006).  
Wertz et al. (1994) set forth several reasons against testing pre-
symptomatic children for genetic conditions. They claim that children with a 
positive test may be made a scapegoat of their test results, and the test results 
could cause adverse effects to that child’s self esteem. For example, the test 
results could cause the child to feel unworthy and the parents to lower their 
expectations for the child. The authors also speculate that test results could 
disrupt family functioning, causing disharmony in parent-child and sibling 
relationships. Finally, the authors are concerned that test results could evoke 
feelings of guilt (Wert et al., 1994).  
Many individuals from a wide range of specialties have voiced their 
opinions regarding predictive testing in asymptomatic minors. Clarke et al. 
(1995) have concerns that test results may result in parents feeling 
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disappointment or rejecting the child. Several individuals have expressed 
concern that knowing a child had a cancer predisposition syndrome would 
raise anxiety in both parents and the child (Clarke, 1994) (American Medical 
Association, AMA ,1995) (Duncan et al., 2001).  Other studies, however, 
have shown that parents are interested in having genetic testing in their 
children so they can plan for their child’s future (Wertz, et al., 1994). 
  Several studies have looked at many aspects of predictive 
testing in children. Yet none have examined feelings that parents with Li-
Fraumeni Syndrome may have towards genetic testing in their children. 
Patenaude et al. (1996) interviewed 47 mothers of children who were 
diagnosed with cancer. Given a scenario of a hypothetical test that could 
detect cancer susceptibility, 13% of participants reported they would decline 
having their child tested due to a lack of family history or preventative 
measures. Mothers were concerned about the anxiety they might encounter 
from learning that a healthy child carried a cancer susceptibility mutation. 
Thirty six percent of participants would agree to have their child tested only if 
knowledge of the results would reduce the risk of cancer development. Fifty-
one percent of mothers would wish to have their child tested for the cancer 
susceptibility gene, despite the lack of potential benefit. Mothers reported that 
they would feel significantly less depressed or anxious if their child did not 
have a cancer susceptibility gene. Alternatively, they did report that they 
would experience depression and anxiety if a healthy child tested positive for 
a cancer susceptibility syndrome. Eight percent of mothers said they would 
not test their healthy children. Mothers had several reasons for this, including 
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their wish to defer the decision to test for their child and fear of insurance and 
social discrimination (Patenaude et al., 1996).  
The researchers then looked at factors that are important mothers’ 
decision to pursue genetic testing in their children. Mothers appeared to be 
consistent regarding what they valued in a genetic test. The most common 
aspects of a genetic test that mothers considered include utility of results and 
their ability to manage health and test reliability. Mothers were also 
concerned about privacy, insurance discrimination and family disruption. 
(Patenaude et al., 1996).  These themes appear to be similar to other 
hereditary cancer syndromes.  
Few reports have been published concerning clinicians’ experience 
with testing minors for LFS. Evans, Lunt, Clancy and Eeeles (2009) depicted 
their experience with testing four children in two LFS families. They reported 
on two families, “Family 1” and “Family 2”. Three children were tested in 
family 1, one set of siblings and the siblings’ cousin. The siblings both tested 
negative for the pathogenic mutation that had been identified in the family. 
These siblings’ parents reported feelings of relief upon hearing the test 
results. The father of the siblings’ cousins was very anxious about that chance 
that his child could have a pathogenic mutation, especially after several recent 
deaths and cancer diagnoses in the family. Unfortunately, this child did have a 
pathogenic mutation. Following the test result, the child’s father did report a 
decline in anxiety despite these results. This child was gradually introduced to 
Li-Fraumeni syndrome and is now an adult considering preimplantation 
genetic diagnosis (Evans, et al., 2009).  
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In “Family 2”, the patient was a nine year old girl who had an 
extensive family history of LFS, including a brother who was diagnosed with 
a cerebral primitive neuroectodermal tumor at ten and died shortly after. A 
p53 mutation had been identified in the patient’s mother after she had 
developed three primary tumors. The patient’s mother was very anxious 
regarding her healthy child’s genetic status and reported that knowledge of 
this would help her manage her daughter’s health. After several counseling 
sessions, the patient underwent genetic testing and was negative. The family 
reported being content with the counseling process. No follow up studies have 
looked at the children’s attitudes towards having been tested at a young age. 
The authors of this article emphasize the point that until there are proven 
medical and psychological benefit to the child, genetic testing decisions for 
LFS should be made carefully on a case by case basis (Evans et al., 2009).  
No studies have examined the emotional impact genetic testing for 
LFS has on children. Familial Adenomatous Polyposis (FAP) is a cancer 
predisposition syndrome that, like LFS, confers a childhood cancer risk. 
Unlike LFS, there are proven beneficial screening modalities in minors with 
FAP. Children with FAP should begin colonoscopy and sigmoidoscopy at 
ages 10 to 11 to evaluate for polyposis (Rozen & Macrae, 2006). In 2001, 
Michie et al. studied the emotional impact genetic testing for FAP has on 
minors. The investigators studied 60 asymptomatic children at risk for FAP 
who had undergone genetic testing. They looked at factors such as anxiety 
and depression. Children who received positive results had a normal range of 
anxiety and depression, although they tended to be more anxious and 
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depressed than children who received negative results. The study also 
explored the difference in anxiety and depression between children and adults 
receiving genetic test results. The group did not find a significant difference 
in either variable between the two groups (Michie, Bobrow& Marteau, 2001).  
In this study, children did not appear to have exaggerated adverse emotional 
impact.  
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a 
hereditary cancer predisposition syndrome which predisposes individuals to 
breast and ovarian cancer (often premenopausal). HBOC does not confer a 
risk of childhood cancer. Genetic testing is therefore not recommended until 
adulthood. In 2008, Bradbury et al. surveyed a cohort of parents and offspring 
with HBOC about their attitudes towards testing minors. Fifty two percent of 
participants reported that they were opposed to testing minors for HBOC, 
some participants felt that genetic testing was only appropriate in minors in 
special scenarios. Individuals who were in favor of testing cited 
implementation of health management guidelines specific to patients with 
HBOC. Although HBOC is clearly very different than LFS, it is interesting to 
see that 48% of these participants are in favor of testing minors, even though 
HBOC does not confer a childhood risk of cancer (Bradbury et al., 2008).  
Li-Fraumeni Syndrome clearly meets the testing criteria of 
conferring a cancer risk in childhood. However, there are no proven benefits 
to implementing screening for cancer in children with Li-Fraumeni 
Syndrome. Due to this discrepancy, testing in children is controversial and 
not standard of care. Currently, in LFS, there are no data looking at parental 
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attitudes towards predictive testing in children. Recently, there has been a 
movement of practitioners testing children for p53 mutations. If the trend in 
testing minors for p53 mutation continues, it is important to describe parental 
attitudes and beliefs towards predictive testing in their children.   
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MATERIALS AND METHODS 
This was a cross-sectional pilot study aimed at describing the attitudes of parents 
of children at risk of inheriting a p53 mutation toward genetic testing in their children. 
This study was approved by MD Anderson Cancer Center’s Institutional Review Board 
(BS99-038) and the Committee for the Protection of the Human Subjects at the 
University of Texas Health Science Center (HSC-GEN-09-0415).   
 
Study Population Identification and Recruitment 
Individuals who had previously participated in LFS genetics research at the 
University of Texas MD Anderson Cancer Center (MDACC) were recruited for the 
study.  The recruitment source was a research database that included data from families 
with Li-Fraumeni Syndrome and was maintained by the Department of Genetics at 
MDACC. The database includes 73 kindreds, and we identified 371 living individuals 
who were at 25% or greater risk of carrying a p53 germ line mutation or who were 
known p53 mutation carriers. Individuals were eligible for the study  if they were: 1) a 
parent of a child younger than 27 years of age who was at risk of inheriting Li-Fraumeni 
Syndrome or previously diagnosed with a LFS-associated cancer, 2) 18 years of age or 
older, and, 3) able to speak, read, and write English.  
Fifty six individuals were identified as being eligible for the study.  Valid mailing 
addresses were available for 20 of the eligible individuals.  We also identified an 
additional 25 deceased individuals from the database who were confirmed or presumed 
p53 mutation carriers, whose children met the above eligibility criteria, and who had a 
surviving co-parent.  Of these 25 individuals, 5 mailing addresses were available for 
surviving co-parents.  
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Data Collection 
Study packets were mailed to 25 eligible individuals and included a cover letter, a 
consent form, a study questionnaire, and a postage-paid return envelope.  The cover letter 
included a description of the study and an invitation to participate, as well as instructions 
for completing and returning the questionnaire.  In the event that the individual in our 
LFS database was deceased, the co-parent was instructed to complete the survey. Co-
parents were given the same survey packet as LFS-affected parents.   Co-parents were 
defined as a surviving spouse of an individual with LFS who is deceased. Parents were 
instructed to complete the written informed consent prior to completing the study 
questionnaire, and to return both the consent form and the completed questionnaire in the 
return envelope.   
 The study was conducted from December 2009 to March 2010.  Study packets 
were mailed in mid-December 2009, and follow-up packets were mailed to non-
respondents at 3 and 6 weeks after the initial mailing. At 4 weeks post-initial mailing, we 
attempted to contact non-responders by telephone to follow up and invite them to 
complete the questionnaire by phone, if they preferred. Three study packets were returned 
without a forwarding mailing address, and one study packet was returned because the 
intended recipient had passed away. Thus, our denominator of eligible individuals was 
reduced to 21.   
 
Measures 
 The selection of study measures was based on several key domains in pediatric 
genetic testing, including attitudes towards p53 genetic testing, communication about 
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testing, stage of change (or readiness) regarding genetic testing, and decisional balance 
(consideration of pros vs. cons). Measures regarding parental communication about  
genetic testing as well as  attitudes and beliefs related to testing were adapted from 
existing instruments used in other studies (Andrews et al., 2006)( Peshkin et al., 2008)( 
Peterson et al., 2008)(Terycak et al., 2001 ). Additional measures were created 
specifically for this study based on domains in the pediatric genetic testing literature.  
The survey was organized into three sections and encompassed the following six 
domains: 1) general attitudes, 2) communication, 3) stage of change, 4) decisional 
balance for parents who have sought testing, 5) decisional balance for parents who have 
not sought testing, and 6) demographics.  We estimated that the study questionnaire took 
about 30 minutes to complete.  No compensation was provided for study participation.    
 
Attitudes toward genetic testing in children  
We included three measures regarding attitudes and interest in genetic testing in 
children. We used the Pediatric Testing Attitudes Scale (P-TAS), an 11-item validated 
measure developed by Peshkin and colleagues (2008). P-TAS was created to determine 
the interest of parents with BRCA1/2 mutations towards genetic testing in their children. 
The P-TAS measures two factors along this dimension: Attitudes and Beliefs (factor 1) 
and Decision Making and Communication (factor 2).  The P-TAS includes 11 statements 
describing attitudes toward testing children for a BRCA1/2 mutation, and respondents are 
instructed to rate each item on a scale of 1 to 5 (1=strongly against genetic testing in 
minors to 5=strongly in favor of it).   Participants were also given the option of “unsure” 
(6).  Score are obtained by summing the individual items. “Unsure” responses were not 
counted in the total P-TAS score. For the present study, we revised the statements to 
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reflect attitudes towards p53 genetic testing.  Higher P-TAS scores were indicative of 
individuals who were in favor of genetic testing in minors, while lower scores were 
indicative of individuals who opposed genetic testing in minors. Our second measure was 
a seven item questionnaire developed specifically for this study. We developed seven 
scenarios when p53 genetic testing may be considered in minors. The participants were 
instructed to determine whether in each scenario, they would pursue genetic testing in 
their child. Participants were given the options of “yes”, “no” and “unsure”.  Finally, we 
included a single item measure aimed at determining at what age the participant thinks 
testing should be considered in minors. This item was initially used in a similar study 
looking at parental attitudes towards testing minors for familial adenomatous polyposis 
(FAP) (Andrews et al., 2006).   
 
Communication with children regarding p53 genetic testing 
 We included a measure adapted from Tercyak et al. (2001) to characterize how 
parents communicated with each child regarding Li-Fraumeni Syndrome and p53 genetic 
testing. This measure was originally developed to evaluate communication between 
mothers with BRCA1/2 mutations and their children about genetics and testing.  The 
measure included four topics regarding communication with children about genetic 
testing. Individuals were asked how frequently they discussed these four topics with their 
child and how comfortable they felt about it.  Items were scored on a scale of 1 to 4 (1= 
not at all, 4= often) (1= not at all, 4 = very). Lower scores indicated less communication 
with children about genetic testing, and higher scores indicated greater communication. 
Two scores were given: 1) communication with child and 2) comfort with 
communication with child.  
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Trans-Theoretical Model 
The Trans-Theoretical Model (TTM) is a psychological and health behavior tool 
that measures and individual’s readiness to implement a behavior (Prochaska & 
DiClemente, 1983) (Prochaska, DiClemente & Norcross, 1992)( Prochaska & Velicer, 
1997). This model, which focuses on the decision making of an individual, consists of 
five “core constructs”: 1) stage of change, 2) process of change, 3) decisional balance, 4) 
self- efficacy, 5) temptation (Prochaska & Velicer, 1997). In this study, we utilized “stage 
of change” and “decisional balance” measures to explain attitudes respondents had 
towards predictive p53 genetic testing in minors. A consistent pattern has been observed 
between the relationship of decisional balance and stage of change (Prochaska & Velicer, 
1997).  
Stage of Change 
 Stage of change is one of five “core constructs” of the Trans-Theoretical Model 
(TTM) (Prochaska, Velicer, 1997). It consists of five discrete levels of behavior change 
or adoption: 1)pre-contemplation 2)contemplation 3)preparation 4) action 5)maintenance. 
We ascertained the steps each parent had taken towards seeking genetic testing for their 
child. Scores were based on a 1 to 5 scale. Individuals were given the option of “I have 
no interest in this”, “I haven’t thought about it”, “I have thought about it”, “I am 
committed to it”, and “I have already done it”. Low scores were indicative of individuals 
who have taken no or few steps towards obtaining genetic testing in their child while high 
scores correlated with individuals who have been active in seeking genetic testing for 
their children.  
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Decisional Balance 
 The decisional balance measure is one of five “core constructs” of the TTM 
(Prochaska, Velicer, 1997).   The items were aimed at determining decisional balance 
(pros and cons) regarding desire to obtain genetic testing in their children.  Items were 
adapted from past studies (Vernon et al., 1999)(Peterson et al., 2008) looking at genetic 
testing attitudes. These items were initially created based on patient and health care 
professional experience (Vernon et al., 1999).  Individuals who have and have not had 
their children tested for p53 mutations were asked to rank the important four “pros”  and 
“cons” in their decision to pursue/decline predictive p53 genetic testing in their children.  
Answers were based on a 1 to 5 point Likert scale (1= not important, 5= very important). 
We aimed to determine how each participant prioritized the positive and negative 
components of predictive p53 genetic testing in minors.  
 
Demographics and Family History 
 We assessed participants’ demographic characteristics including gender, marital 
status, education, occupational status and household income. Additional demographic and 
family history information such as age, race, ethnicity and family history of LFS-related 
cancer and death  was obtained through existing information in the MDACC database. 
 
Data Analysis 
 Data were entered into an excel spreadsheet. Descriptive statistics were run on the 
data. We first analyzed each individual participant’s responses. The participants were 
then analyzed as a group. Next, we divided the participants in two groups: those who 
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have tested their children and those who have not tested their children. As our sample 
size is small (n=6), we did not feel it was appropriate to perform statistical tests of 
association or other analyses.  
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RESULTS 
 
Demographics 
  Of the 21 potentially reachable participants, 6 returned the survey, with a 
response rate of 6/21 (28.57%). Two of the participants were co-parents, while the other 
4 belonged to our original Li-Fraumeni Syndrome cohort.   Three participants (50%) 
were male and three (50%) female.  Four individuals were married (66.67%), while the 
other two were widowed. Education level of the participants varied with one completing 
some high school, two completed some college, two were college graduates and one had 
an upper level degree.  Most individuals held either full or part time employment, while 
one participant was unemployed and seeking a job. Of note, one participant was disabled 
from a diagnosis of terminal cancer Annual household income ranged from $25,000-
$50,000 per year (50%), to >$75,000 per year.  Table 1 summarizes participants’ 
demographic profiles.  
 Table 1b describes characteristics of each respondent and/or co-parent. Three 
respondents were co-parents of individuals with p53 mutations who have passed away. 
Of the remaining 3 participants, 2 had a p53 mutation, while 1 did not. Ages of the 
respondents/ co-parents ranged from 35-52 years. 
 Data from 6 families with 12 children were available for study. Five of the 
individuals who completed the survey had children (Table 2). The sixth participant did 
not have children. On average, the families had 2.4 children, with ages ranging from 15 
to 22 years. Three children from 2 families were deceased at ages 6, 9 and 23. All of 
these children were reported to have died from cancer.  Of the offspring reported in the 
survey responses, 8 (66.67%) were female, and 4 (33.33%) male.   
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Table 1. Demographic Characteristics of Participants 
 Number %   Number % 
Total 
Participants 
(N) 
6  Occupation   
   Employed (full 
time) 
2 33.33% 
Gender   Employed (part 
time) 
2 33.33% 
Male 3 50% Unemployed 
(seeking job) 
1 16.67% 
Female 3 50% Disabled  1 16.67% 
      
Marital Status   Annual Household 
Income 
  
Married 4 66.67% $25,000 – $50,000 3 50% 
Widowed 2 33.33% $50,000 - $75,000 1 16.67% 
   >$75,000 2 33.33% 
Education   
Some high 
school 
1 16.67% 
  
Some college 2 33.33% 
College 
graduate 
2 33.33% 
Upper level 
degree 
1 16.67% 
 
 
 
38 
 
 
Table 1b.  Respondent characteristics 
Family Vital Age/Age 
of Death 
Gender Genotype Respondent 
1 Living 50 Male Mutation Self 
2 Living 50 Female Wild 
type 
Self 
3 Deceased 37 Male Mutation Co-parent 
4 Deceased 43 Female Mutation Co-parent 
5 Deceased 35 Female Mutation Co-parent 
6 Living 52 Female Mutation Self 
 
 
 
 
 
 
Table 2. Child information 
Family Child Vital Age Cause of death Gender 
1 Deceased 9 Unspecified cancer Female                 
1 2 Deceased 23 Unspecified cancer Female  
1 Alive 22 NA Female 
2 Alive 21 NA Female 
 
2 
3 Alive 20 NA Female 
1 Alive 20 NA Male  
3 2 Alive 18 NA Male 
1 Alive 20 NA Male 
2 Alive 16 NA Female 
 
4 
3 Alive 15 NA Female 
1 Alive 16 NA Female  
5 2 Deceased 6 Unspecified cancer Male 
39 
 
 
Figure 2. Survey response dichotomization 
 
Questionnaire Response 
P-TAS (Pediatric Testing Attitudes Scale)  
 All six participants completed section one of the questionnaire. P-TAS scoring is 
based on a 1-5 scale, with lower scores indicating attitudes against testing and higher 
scores indicating attitudes in favor of testing. This was an 11-item scale, scores could 
potentially range from 11 (strongly against testing) to 55 (strongly in favor of testing). 
The P-TAS scores from this survey ranged from 38-55, with an average of 45.833, 
indicating strong attitudes towards p53 testing in children (Table 3). The creators of the 
P-TAS model further divided the questionnaire into two factors, 1) attitudes and beliefs 
and 2) decision making and communication. These factors are believed to assess parents’ 
attitudes in pediatric p53 testing. The average scores were 4.42 and 4.22 for factors 1 and 
2, respectively. Scores for factor 1 ranged from 3.2 to 5, while factor 2 scores ranged 
from 3 to 5 (Table 4).  
6 surveys  
No children 
(n=1) Children (n=5) 
Tested 
(n=2) 
5 individuals  
Not Tested 
(n=3) 
6 individuals  
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Table 3. P-TAS responses 
 Stro
ngly 
Disa
gree 
Disa
gree 
Neit
her 
Agr
ee 
nor 
Disa
gree 
Agr
ee 
Stro
ngly 
Agr
ee 
Uns
ure 
1. Children under age 18 should be given the opportunity to be 
tested for the p53 mutation 
   2 
33.3
3% 
4  
66.6
7% 
 
2. Parents should decide if their children are allowed to have a 
p53 test or not, even if a doctor disagrees 
   1 
16.6
7% 
4 
66.6
7% 
1 
16.6
7% 
3. Even though some of the cancers associated with p53 
mutations do not affect children until they reach adulthood, 
children should still be offered p53 testing 
  1 
16.6
7% 
1 
16.6
7% 
4 
66.6
7% 
 
4. Children should be involved in making the decision about 
whether or not they participate in p53 testing 
1 
16.6
7% 
 1 
16.6
7% 
1 
16.6
7% 
3     
50% 
 
5. If children are tested and they carry a p53 mutation (that is, 
they test positive), they should be told about their test result 
immediately 
1 
16.6
7% 
 2 
33.3
3% 
2 
33.3
3% 
1 
16.6
7% 
 
6. Even if there is no known prevention, treatment, or cure for 
the cancers associated with p53 mutations, children should be 
offered p53 testing 
   3      
50% 
3       
50% 
 
7. If children are tested and they turn out to carry a p53 
mutation (that is, they test positive), then this information 
should be shared with the child’s pediatrician. 
   2 
33.3
3% 
4 
66.6
7% 
 
8. I want my child to be tested for a p53 mutation before age 18 
* 
 1      
20% 
 1     
20% 
3          
60% 
 
9. If children are tested and they do not carry a p53 mutation 
(that is, they test negative), they should be told about their test 
result immediately * 
1       
20% 
 1          
20% 
1         
20% 
2       
40% 
 
10. The benefits of children participating in p53 genetic testing 
outweigh the risks 
  2 
33.3
3% 
1 
16.6
7% 
3     
50% 
 
11. I am in favor of p53 gene testing for children 
 1 
16.6
7% 
  4 
66.6
7% 
1 
16.6
7% 
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Family 
Table 4. P-TAS and Factor Analysis 
Family Total    
P-TAS 
Factor 1 
(average) 
Factor 2 
(average) 
1 52 5 4.4 
2 46 4.5 4.75 
3 42 3.83 3.75 
4 42 5 3 
5 55 5 5 
6 38 3.2 4.4 
Average 45.833 4.42 4.22 
52
46
42 42
55
38
46
55
11
0
10
20
30
40
50
60
1 2 3 4 5 6 Average In favor Against
Chart 1. P-TAS Scores
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1.00
0.90
0.77
1.00 1.00
0.53
0.88
0.76 0.76
0.48
1
0.88
0
0.2
0.4
0.6
0.8
1
1.2
1 2 3 4 5 6
Factor 1
Factor 2
Chart 2. P-TAS Factor Scores
Family
P-
TA
S R
at
io
 
Scenario Decision Making 
Participants were given a scenario and asked if they would be in favor of p53 gene 
testing for their child. All participants indicated that they would be in favor of testing if 
any of their children had developed cancer, if the results would help manage the health of 
that child or help another family member in any way. Most individuals (n=4, 80%) would 
be in favor of testing if the child agrees to or requests testing, while one was unsure. Table 
5 summarizes these results.  
Participants varied when asked at what age it is appropriate to test a child for a p53 
mutation. Responses included numerical responses such as 13, 18 or 21. 
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  Others made comments such as “ASAP” and “As early as possible without 
child knowing, one or above”. Table 6 summarizes these results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Scenario Decision Making 
 Yes Unsure  
 n % n %  
 
My child has 
developed cancer 5           
100% 
 
  
 
One of my other 
children has developed 
cancer  
5 
100% 
 
  
 
He/She agrees to have 
testing 4 
80% 1 20%  
 He/She requests testing 4 80% 1 20%  
 
He/She is older than 
ten 
3 60% 2 40%  
 
If the results would 
help manage my 
child’s health 
5 
100% 
 
  
 
If results would help 
other family members  5 
100% 
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Communication  
Communication was characterized by a model created by Tercyak et al. (2004). 
Individuals were asked how frequently they discussed topics pertaining to p53 mutations 
and genetic testing and how comfortable they were with this discussion (or lack thereof).  
Five individuals completed this section for a total of 11 children (Table 7). Three parents 
reported sometimes talking to their children about p53 genetic testing, while 2 parents have 
never had this discussion. Of the individuals who have spoken with their children about 
this issue, all of them felt either mostly or very comfortable with it. Only two parents have 
asked children how they felt about genetic testing often, one individual reported having 
this discussion sometimes, while two parents never have had this conversation. All of the 
individuals who have asked their child their feelings towards p53 testing felt either mostly 
or very comfortable with the discussion.  Most participants’ responses did not vary 
 Table 6. Age of testing responses 
Family  At what age do you feel it is appropriate to test 
an individual for a p53 mutation?   
1 ASAP 
2 No answer 
3 Should be based on the individual child. Too many 
variables to establish one specific age. 
4 As early as possible without child knowing. One or 
above. 
5 13 
6 18 or 21, depends on the child (adult)? 
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between children. One participant (4) did vary their responses between his/her three 
children. It is unclear why these results are discrepant. 
Stage of change 
Five participants with a total of 11 children completed the stage of change 
questionnaire. Participants varied regarding the steps they have taken towards seeking 
genetic testing for their child. Two individuals have reportedly had p53 genetic testing on 
all of their children (n=3) and shared the child’s results with him/her.  Others have thought 
about (n=2) or are committed to (n=1) discussing p53 genetic testing with their child and 
seeking more information about the subject. One individual has reportedly not thought 
about seeking information or meeting with someone to discuss p53 genetic testing. One 
individual is committed to have their child tested for a p53 mutation, while two individuals 
have thought about it. Individuals gave consistent answers for each of their children. Table 
8 reviews these responses. 
Testing motivations – child tested 
Two of the five participants have sought genetic testing for their children (n=3).  
Table 9 depicts their responses to the testing motivation questionnaire. Family number one 
reported testing both of their children prior to their death.  Family 1 reported that the 
possibility of relief to know that their child did not have a p53 mutation was “important”, 
while family number two ranked it as “very important”. Both families ranked their 
family’s experience with cancer and the level of concern about their child it has caused as 
“very important”. Likewise, both families ranked the possibility of their child undergoing 
preventative measures or planning for their future as “very important”. Participants’ 
responses did not vary between children.  
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Testing motivations- child not tested  
The three families whose children have not had p53 genetic testing answered 
similar questions about what their motivations would be towards seeking testing (table 10) 
Family 3 ranked relief from knowing their child does not have a mutation as “slightly 
important”, while families four and five ranked it as “very important”. Family 3 said that 
their family’s experience with cancer making them more concerned is “somewhat 
important”, while families 4 and five ranked family experience with cancer  as “very 
important”. The chance that their child could do something to lower his/her risk was 
“somewhat important” to family 3, “important” to family 4, and “very important” to family 
5. Family 5 thought that the possibility that they or their child could plan for the child’s 
future was “very important”, family 3 thought it was “somewhat important”, and family 4 
thought it was “slightly important”. Participants’ responses did not vary between children.   
Family 6 did not complete this questionnaire because they do not have children.  
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Table 7. Communication    
How often have you: How comfortable were you with this?  
 Not 
at 
all 
 
Rarely 
 
 
 
 
 
 
Some- 
times 
 
Often  
Not 
at 
all 
  
A 
little 
bit 
Mostly  Very 
 
Talked with 
this child 
about 
genetic 
counseling 
and testing 
for p53? 
3,4  1,2,5  4(2,3)*  3,5 1,2 
Asked this 
child how 
he/she felt 
about 
genetic 
testing? 
3,4  
2 
 
1,5 4(2,3)*  2,3,4(1)* 1,5 
Tried to 
reassure this 
child that 
he/she 
would be 
OK? 
** 
4   1,2,5 4(2,3)*  4(1)* 1,2,5 
Tried to 
reassure this 
child YOU 
would be 
ok? 
4 3  1,2,5 
 
4(2,3)*  3,4(1)* 1,2,5 
*Parenthesis indicate instances when individuals responded differently for each child. 
Numbers inside parenthesis represent which child each response was intended.  
** Participant 3 did not respond to this item 
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Chart 3. Communication Scores 
 
 
 
 
 
 
 
 
 
 
Table 8. Stage of Change 
n= 5 families (11 
children) 
I have 
no 
interest 
in this 
I haven’t 
thought 
about it 
I have 
thought 
about it 
I am 
committed to 
it 
I’ve already 
done it 
 n % n % n % n % n % 
Discussed genetic 
testing with this child     2 40% 1 20% 2 40% 
Sought information 
regarding testing for a 
p53 mutation in this 
child 
  1 20% 1 20% 1 20% 2 40% 
Made an appointment 
with a doctor/genetic 
counselor 
  2 40% 1 20%   2 40% 
Met with a 
doctor/genetic 
counselor 
  1 20% 2 40%   2 40% 
Had this child tested for 
a p53 mutation     2 40% 1 20% 2 40% 
Shared  these results       1 33.33% 2 66.67% 
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Testing concerns  
Five families with a total of eleven children completed the “testing concerns” 
section of the questionnaire. Participants were asked to rank the importance each factor 
was/is when considering pediatric genetic testing (Table 11). Most individuals (n=4) stated 
that the concern that they or their family would get too upset about test results was “not 
important”, while one individual ranked it as “somewhat important”. The concern that their 
child would get too upset was somewhat important to three individuals and slightly 
important to two individuals. The majority of participants (n=4) cited concern about 
insurance discrimination and test results affecting their child’s future as “very important”. 
Participants responses regarding the lack of management or prevention techniques for 
individuals who have p53 mutations varied from “not important” (n=1), “somewhat 
important” (n=1) and “very important” (n=2). Most of the participants’ responses did not 
vary from child to child. One individual did vary their responses between children.  
In addition to the quantitative results previously discussed, our questionnaire 
included several opportunities for respondents to provide additional comments. Table 11 
consists of comments the respondents shared with us in open-ended opportunities.  
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Table 9. Testing motivation (tested)  
 
n=2 families , 5 children Important Very Important 
 
I would have been relieved to know 
that my child did not have a p53 
mutation 
Fam. 1 Fam.2 
 
My family’s experience with cancer 
made me more concerned about my 
child’s own risk for the disease 
 
Fam. 1    
Fam.2 
 
My  child could do something to 
lower his/her cancer risk  
Fam. 1      
Fam.2 
 
I / My child could plan for the future 
 
Fam. 1     
Fam.2 
 
19
20
11
15.67
20
17.134
4
20
0
5
10
15
20
25
1 2 3 4 5 Average Minimum Maximum
Chart 4. Decisional Balance: Pros
Sc
or
e
Family
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Table 10. Testing motivations (not tested) 
 Slightly 
Important 
Somewhat 
Important Important 
Very 
Important 
n=6 children from 3 
families 
n % n % n % n % 
I would have been 
relieved to know that 
my child did not have a 
p53 mutation 
3 33.33%     4, 5 66.67% 
My family’s experience 
with cancer made me 
more concerned about 
my child’s own risk for 
the disease 
  3 33.33%   4, 5 66.67% 
My  child could do 
something to lower 
his/her cancer risk 
  3 33.33% 4 33.33% 5 33.33% 
I / My child could plan 
for the future 
4 33.33% 3 33.33%   5 33.33% 
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Table 11. Testing concerns 
 
n=5 
families, 11 
children 
Not Important Slightly Important 
Somewhat 
Important Important Very Important 
 
I’m afraid I 
would get 
too upset 
1,2,3,4 80%   5 20%     
 
I’m afraid 
my child 
would get 
too upset 
  1,3 40% 2,4,5 60%     
 
I am 
concerned 
that having 
the test 
might cause 
problems 
with my 
child’s 
insurance 
    1 20%   2,3,4,5 80% 
 
There is 
nothing my 
child can do 
about 
getting 
cancer 
1,4 40%   3 20%   2,5 40% 
 
I am 
concerned 
about my 
family’s 
reaction 
1,3,4,5 80% 2 20%       
 
I am 
worried 
about how 
it could 
affect my 
child’s 
future 
    3(1)* 10% 3(2)* 10% 1,2,4,5 80% 
• Parenthesis indicate instances when individuals responded differently for each 
child. Numbers inside parenthesis represent which child each response was 
intended.  
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Table 11. Additional Comments 
Family Comment 
1 Info is power 
3 I have not had my children tested because their father's opinion/request 
was not having them tested. He felt that being aware of the risks and 
having regular checkups would be a better option. He feared if they were 
tested positive, it could have adverse affects. I.E. ability to get health or 
life insurance, psychological since their father lost his battle with cancer, 
etc. As young adults I need to educate them with their options and allow 
them the choice at some point 
I want to know as a parent. My kids already know they are at a greater 
risk because of being related to my wife's family. I do not want them to 
know results until all 3 are ready as adults. I do want their doctors to 
know.  
 
I do not want my kids to know results or even what the test is looking for 
until all 3 are adults or if one develops cancer. If one finds out, the others 
will worry.  
 
I don't want my kids to know results or even the real reason for the test 
other than testing them is for research. Would prefer if draw made by 
family doctor as "routine" blood work. I do want to know and I also want 
my family doctor to know (verbally).  
 
4 
It would justify testing that could give early detection, allowing better 
odds on treatment.  
 
We have recently been discussing with (proband’s)15 year old daughter 
about getting her tested for (LFS).    
 
5 
We are living with the effects that losing a mother and a brother because 
of (LFS), has on a child.  The worries and the fears that are created when 
she is ill or just doesn’t feel good.  (Daughter) is constantly worried 
about developing cancer and it has created a major impact on all of our 
lives. 
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Discussion 
  
Pre-symptomatic testing for p53 mutations is clinically available and the choice to 
test a child for these mutations is typically left to the parents and physician of the child. 
The decision whether to have a minor-aged child tested for a cancer predisposition gene 
such as p53 is composed of several factors (Patenaude et al., 1996). This study looks at 
parental attitudes towards testing children for p53 mutations. We looked at factors such as 
basic attitudes towards genetic testing, communication with children and used the Trans-
theoretical model to assess decisional balance and stage of change. This is the first study to 
examine the attitudes of parents towards testing their children for p53 mutations.  
Demographics and family characteristics 
 The demographic characteristics of our participants appear to be unremarkable. 
Among the six respondents, there is no clear pattern in terms of gender, marital status, 
education, employment our annual household income. Age of respondents also appeared to 
be insignificant. Of note, the survey was sent to households with children who are a variety 
of ages. All of the participants with living children who responded had children between 
15 and 23 years of age. It is interesting that no individuals with younger children chose 
respond to the study.  The average age of living children to individuals who did not 
respond to the survey was 17.4 years with ages ranging from 1 to 35 years.   
Questionnaire 
Pediatric Testing Attitudes Scale (P-TAS) 
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The pediatric testing attitudes scale (P-TAS) is a measure developed my Peshkin et 
al. (2009) to ascertain parental attitudes towards testing minors for BRCA1/2 mutations.  
This eleven-item scale was divided by its creators using principal components extraction 
method with rotation of factors in two factors: 1) attitudes and beliefs (six items), and 2) 
decision making and communication (five items). Scores from each factor were summed to 
give the total P-TAS score for each participant with a minimum of 11 and maximum of 55. 
Higher scores were indicative of parental attitudes more strongly in favor of pediatric p53 
genetic testing, while lower scores indicated parents who were more opposed to testing 
their children for p53 mutations.   
Scores from our six participants ranged from 38 to 55 with an average of 45.833. 
These scores indicate that parents were mostly in favor of obtaining p53 genetic testing for 
their children, although scores varied. When scores are divided into their two factors, an 
interesting observation can be made. Factor 1 is composed of 6 items regarding attitudes 
and beliefs about p53 genetic testing in minors, with a minimum and maximum score of 6 
and 30, respectively. The average factor 1 score from our six participants is 26. 
Respondents seem to be consistently “in favor of”, or “strongly in favor of” most items 
regarding minors having the opportunity to be tested for p53 mutations. Sample items from 
factor 1 include: “children under age 18 should be given the opportunity to be tested for 
the p53 mutation”, and “even if there is no known prevention, treatment, or cure for the 
cancers associated with p53 mutations, children should be offered p53 testing”. Only one 
individual reported that they did not want their children tested for p53 mutations before the 
age of eighteen, although they appeared to believe that children and parents should be 
given the opportunity to make that decision.  In total, parents seemed to agree that all 
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children should have the right to be tested for p53 mutations, although not all would 
personally test their child or children. 
Factor 2 pertains to decision making and communication (Peshkin et al., 2009). 
Sample items from factor 2 include statements such as:  “Children should be involved in 
making the decision about whether or not they participate in p53 testing” and “If children 
are tested and they turn out to carry a p53 mutation, they should be told about their test 
result immediately. Factor 2 consisted of five items which were totaled to make a 
minimum and maximum score of 5 and 25, respectively. Respondents’ factor 2 scores 
ranged from 12 and 25 with an average of 19.83. Individual responses to these items 
varied. While most people believed that parents should be able to make the decision to test 
their child for a p53 mutation, respondents did not agree whether children should be 
involved in the decision making process. One individual strongly disagreed that children 
should take a part in this decision, while others were either unsure or agreed. That same 
individual was strongly against sharing the child’s genetic testing results with him/her 
regardless of if the testing identified a mutation. This respondent did, however agree that 
the information should be shared with the pediatrician.  While some individuals would 
apparently readily involve their child in the testing decision, others would prefer to make a 
decision on behalf of their child. 
 
Testing Scenarios 
All participants reported that they would test their child for a p53 mutation if that 
child had developed cancer, or if the child’s sibling developed cancer. Other studies have 
demonstrated that parents would be more likely to test a child who has already developed 
cancer for a cancer susceptibility gene, than a healthy child (Patenaude et al., 1996).  The 
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question of pre-symptomatic testing in minors becomes more complex. Four individuals 
would test their child if the child consented to or even requested testing, while one was 
unsure. Three individuals would test their child if he/she was over the age of ten, while 
others were unsure. Finally, all individuals would test their child for a p53 mutation if 
results would help manage that child’s health or help other relatives. Although the option 
of “no” was given, respondents never chose it for any of the seven scenarios. Parents most 
likely recognize that the decision to test their child for a p53 mutation is composed of 
several factors which must all be considered in light of each child/family’s unique 
situation.  
 
Age 
Parents varied in their response regarding the appropriate age would be to test 
children for a p53 mutation. Family 1, who had two children die from cancer related issues 
reported that he thought children should be tested for p53 mutations as early as possible. 
Family 4 agreed that children should be tested as early as possible but added that the child 
should not know about the test or results. Family 4 is consistent throughout the survey in 
their attitude about not wanting their children to know the results of the test.  Family 
number five believes children should be tested at age 13. At this age, minors are often 
thought to be able to make their own meaningful decisions, and it may therefore some may 
consider it reasonable to allow these children to participate more in their healthcare 
decisions. Family 3 reported that the age to test a child for p53 mutations “should be based 
on the individual child” and that there are “too many variables to establish one specific 
age”.  This statement may refer to the fact that children, regardless of age have varying 
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cognitive abilities, maturity, and decision making capabilities. Some mature adolescents 
may have the same mental capacities that are associated with autonomous agents (Kon, 
2006), while others may not. Other factors such as health of the child and their siblings, 
family history and other psychosocial characteristics that are unique to that child may also 
play a role in a parent’s decision of when to test their child.  Family 6 stated that 
individuals should be tested for p53 mutations at the age of 18, or 21, depending on the 
individual.  This individual seems to be taking a more conservative stance on genetic 
testing and believes that it should be postponed until the child has reached the age of 
majority (18 in most states) or age of license (varies) . The age of majority refers to the age 
at which a child transitions to an adult and assumes responsibility of his or her own self, 
decisions and responsibilities. At this age, the child is no longer under jurisdiction of their 
parent or guardian. Age of license refers to the age at which an individual gains certain 
privileges. For instance, 21 is often the age of license for consumption of alcoholic 
beverages and participation in gambling activities. Family 6 appears to associate these ages 
with the ability of an individual to make reasonable and well thought decisions about their 
healthcare. 
Communication 
 Past studies indicate that the frequency of communications parents have with their 
children about family history of cancer, genetic testing and general child and parental 
health correlates with interest in genetic testing and disclosure of results (Terycak et al., 
2002)(Tercyak et al., 2006).  Overall, families varied in regard to how frequently they 
communicated with their children about these issues. Families 3 and 4 were consistent 
non-communicators. They do not appear to have open communication with their children 
with regard to genetic testing and parental/child health. Family 4 appears to be fairly 
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consistent in their attitudes about not wanting to involve their children in any of the 
decision making processes of genetic testing. While family 3 did not make any other 
revealing comments about not wanting to involve their children in the decision to test, they 
do not appear to be having active discussions about the issue.  
 Other families reported that they sometimes spoke with their children about genetic 
counseling and testing for p53 mutations and felt mostly or very comfortable with it. These 
individuals also sometimes or often asked their child how he/she felt about genetic testing 
and seemed comfortable with those discussions. These families seem to have open 
communication with their children about p53 genetic testing and most likely their child’s 
input. Most individuals report frequently reassuring their child about their own health and 
that child’s health. Those who have this discussion appear to be fairly comfortable with it. 
Although our sample size is small, the results are consistent with research done by Tercyak 
et al. (2002). The two families who have already had their child tested for p53 genetic 
mutations appeared to be very open with their children about p53 genetic testing. Others 
who reported less frequent communication with their children have not taken steps towards 
seeking testing in their children. 
Trans-theoretical Model 
The trans-theoretical model (TTM) has been used extensively in health-related 
studies looking at intentional behavior change (Prochaska & DiClimente, 1983) 
(Prochaska, DiClemente & Norcrow, 1992) (Prochaska & Velicer, 1997). The model is 
composed of five core constructs: 1) stages of change, 2) processes of change, 3) 
decisional balance, 4) self-efficacy and 5) temptation (Prochaska & Velicer, 1997). In our 
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study, we used the stage of change and decisional balance measures to explain attitudes 
towards p53 genetic testing. 
Stage of Change 
The stage of change measure is composed of a series of five changes: 1) pre-
contemplation, 2) contemplation, 3)preparation, 4) action and 5) maintenance (Prochaska 
& Velicer, 1997).  Pre-contemplation refers to the stage when individuals do not intend to 
make an action in the next 6 months (Prochaska & Velicer, 1997). In our questionnaire, the 
pre-contemplation stage is represented by two items: have individuals discussed testing 
with their children and have they sought information regarding testing. All of the 
respondents have at least considered talking with their children about genetic testing. Some 
answers to this section were not consistent with respondents’ answers to the 
communication measure. Only two individuals reported that they have already discussed 
genetic testing with their child, while three individuals reported that they have sometimes 
talked with their child about genetic testing in the communication measure. It is not clear 
why these responses are discrepant.  Individuals who are in the contemplation stage are 
intending to change in the next six months (Prochaska & Velicer, 1997). In most cases, 
they have thought seriously about the decision to change, such as the pros and cons. 
Individuals who are in the contemplation stage in obtaining p53 genetic testing for their 
children have presumably sought information or made an appointment with a physician or 
genetic counselor.  Most families have at least thought about seeking information and 
making a counseling appointment.  Two families reported that they had not thought about 
seeking information about testing, while one has not thought about making a genetic 
counseling appointment. These individuals do not appear to be seriously considering 
genetic testing in their children, although in previous sections of their survey, they 
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appeared to be in favor of pediatric genetic testing in minors. The preparation stage refers 
to the stage when people plan on taking action in the immediate future (Prochaska & 
Velicer, 1997). In our study, individuals who have met with a physician or genetic 
counselor were in the preparation stage. Only two individuals reported that they have met 
with a physician/genetic counselor, while the rest have either not thought about it, or have 
thought about it and not acted on it.  
Only two individuals (families 1 and 2) have had their children tested for p53 
mutations, thus completing that action stage (the stage in which people have implemented 
a change or action) (Prochaska & Velicer, 1997).  One family is committed to this, while 
two have thought about it. Both individuals who tested their children have disclosed the 
results to those children. Another individual is committed to sharing genetic results with 
their child once that child gets tested. Overall, only two individuals have gone through all 
of the stages of change and even disclosed results to their children. Others appear to be still 
in the pre-contemplation stage.  Among those in the pre-contemplation stage, some 
individuals seem to be more interested in genetic testing than others, by saying that they 
are committed to having their child tested for a p53 mutation and disclosing those results. 
Other families do not appear to have contemplated to subject. 
Decisional Balance 
Decisional balance refers to the weighing of pros vs. cons of implementing a 
behavior or change (Prochaska & Velicer, 1997). How an individual weighs the pros and 
cons of a decision is thought to predict their stage of change. For instance, a person who is 
only in the contemplation stage might rate the pros and cons equally, while someone who 
is in the action stage might rate the pros higher than the cons. If this is true, individuals 
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who have tested their children for p53 mutations should have higher “pros” scores than 
“cons” scores. In fact, this is the case. The pros scores for families 1 and 2 are 0.95 and 
1.0, respectively, while the cons are 0.52 and 0.84. Both families seemed to value the pros 
more than the cons.  Likewise, individuals who are still considering p53 genetic testing 
should have a near balance of “pros” and “cons”. Families 3,4 and 5 had “pros” scores of 
0.55, 0.8, and 1.0, respectively and “cons” scores of 0.62, 0.64 and 0.84. With the 
exception of family 5, families 3 and 4 and lower “pros” scores than the two families who 
tested their children. It is possible that they have not pursued p53 genetic testing in their 
children because they do not see value in results. Family  5 has “pro” and “con” scores 
identical to family 2, but has not tested their child for p53 mutations. They did, however, 
indicate that they are committed to testing their child for p53 mutations and disclosing 
those results to that child. The decisional balance appears to be a predictable indicator of 
stage of change in this small sample.  
Regardless of whether their children have undergone genetic testing, most 
individuals (n=4, 80%) ranked that their family’s experience with cancer increasing their 
concern about their child’s risk as “very important”. Likewise, most (n=4,80%) ranked the 
relief they would feel if their child did not have a p53 mutation as “important” or “very 
important”. It is interesting to note that those who tested their children for p53 mutations 
ranked the possibility that test results could manage their child’s health or help plan for the 
child’s future as “very important”, while only one of the individuals who have not tested 
their children chose the same ranking. This is the same individual who is committed to 
testing their child. Other families ranked it as “somewhat important” and “important”.  It 
appears that individuals who have not had their children tested for p53 mutations see a lack 
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of potential benefit for the child’s health or planning for the future. How families perceive 
the utility of testing appears to influence how they weigh the “pros” and “cons”. 
Families uniformly ranked the possibility that they would have a negative reaction 
to test results as “not important” or “somewhat important”. Likewise, individuals were not 
concerned about their family’s reaction, indicating that it was either “not important” (n=4, 
80%), or “slightly important” (n=1, 20%). Families seem more concerned about the 
reaction of the individual child being tested for a p53 mutation, ranking concern about the 
child’s reaction as “slightly important” (n=2, 40%) and “somewhat important” (n=3, 60%).  
These families appear to be taking a protective role in being concerned about their child’s 
reaction over their own. 
Eighty percent (n=4) of respondents ranked concern about insurance discrimination 
as “very important”. This is consistent with other studies which cite concerns about 
insurance discrimination as major deterrents to pre-symptomatic genetic testing. 
Individuals do not appear to feel protected by the Genetic Information Non-discrimination 
Act (GINA), which was implemented in the fall of 2009 (Erwin, 2009). GINA protects 
pre-symptomatic individuals from discrimination by health insurance companies and 
employers (Slaughter, 2008) (Erwin, 2009). GINA does not protect pre-symptomatic 
individuals from life or long term disability insurance (Slaughter, 2008). It remains to be 
seen whether the country’s health care reform will change how individuals feel about 
insurance discrimination.  
There were no clear patterns between the families who have tested their children 
and those who have not in how they ranked the “cons”, with the exception of one item. 
One item (there is nothing my child can do about getting cancer) was particularly varied, 
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with answers ranging from “not important” to “very important”. Family 1, who tested their 
child, and family 4, who did not test their child ranked it as “not important”. Families 2 
and 5 ranked this item as “very important”. Family 2 tested their child while family 5 is 
committed to it. Interestingly, these families ranked the “pro”: my child could do 
something to lower his/her cancer risk as “very important”.  These responses appear to be 
contradictory.  
Other Comments 
  Respondents were given several opportunities throughout the questionnaire to 
provide qualitative responses. These comments were especially revealing. While some 
responses reinforced the themes which have presented themselves in the quantitative data, 
others introduced new issues which would be interesting to address in future studies. 
Family 1 indicated that “info is power”. This family tested their children for p53 
genetic mutations. The respondent had two daughters, who both passed away from cancer-
related issues. Additionally, the respondent has a diagnosis of a terminal cancer. This 
family has quite a significant history of cancer diagnoses and subsequent deaths. It is 
possible that this individual feels that knowing whether his children had the cancer 
susceptibility gave him some kind of control, although both his children presumably had 
p53 mutations. Power can be translated in a number of ways. While power can mean that 
knowing genetic results may benefit the child’s health management, it may also mean that 
it can allow the family to plan for the future, make lifestyle choices, etc.  
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Respondent 3 provided the following statement:  
 
 
 
 
 
This  response highlighted several key issues. This is a co-parent whose spouse had 
passed away from cancer-related issues. First, this individual is respecting her partner’s 
wishes. It is clear that the couple had put a lot of thought into this topic before the father 
passed away, and that they had made a choice together to defer testing until the children 
had reached adulthood. The couple appeared to be concerned about several issues. 
Insurance discrimination is a theme which continues to present itself both here and in other 
studies related to pre-symptomatic testing for cancer susceptibility (Patenaude et al., 1996). 
The couple also feared that watching a parent with LFS die from cancer would cause the 
children more anxiety when going through genetic testing themselves.  It appears that this 
individual is very knowledgeable about LFS and associated risks. She is making it her 
responsibility to be vigilant about the health of her children and to share information and 
help facilitate decision making when the children get older.  
  
 
 
“ I have not had my children tested because their father’s 
opinion/request was not having them tested. He felt that being 
aware of the risks and having regular checkups would be a better 
option. He feared that if they were tested positive, it could have 
adverse affects. I.E. ability to get health or life insurance, 
psychological since their father lost his battle with cancer, etc. As 
young adults I need to educate them with their options and allow 
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Respondent 4 provided comments: 
 
 
 
 
 
 
 
 
In previous sections, this individual indicated that he was in favor of predictive p53 
genetic testing in children. However, he was strongly against involving children in the 
decision making process and disclosing results to them. These qualitative comments are 
consistent with the quantitative responses. This individual appears to believe that testing 
would benefit the health of the child in some way but feels the need to play the role of 
gatekeeper with this information. The children of this individual are ages 15, 16 and 20.  
This individual’s responses are especially interesting considering the ages of his children, 
one of which is considered to be past the age of majority, and is legally able to request 
his/her own testing without parental permission. The other children may be considered to 
be at the age of “assent”. It would likely be difficult to find a physician or genetic 
counselor willing to test children of these ages without their assent.  
“I want to know as a parent. My kids already know they are at a greater risk 
because of being related to my wife’s family. I do not want them to know 
results until all 3 are ready as adults.” 
“I do not want my kids to know results or even what the test is looking for until all 
3 are adults or if one develops cancer. If one finds out, the others will worry.” 
“I don’t want my kids to know results or even the real reason for the test other 
than testing them is for research. Would prefer if draw is made by family doctor 
as “routine” blood work. I do want to know and I also want my family doctor to 
know (verbally).” 
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The issue of genetic testing in minors is becoming increasingly prevalent. One key 
component is the concept of “assent”.  For minors in healthcare, assent refers to the minor 
understanding and agreeing to the proposed procedure or test (De Lourdes, Larcher & 
Kurz, 2003).  
 In his comments, respondent 4 appears to have concerns about insurance 
discrimination. He reports that he would want his childrens’ doctor to know test results 
“verbally”. This individual presumably does not want genetic results to be documented in 
their child’s medical record, which health insurance companies or other potentially 
discriminating persons could access. Once again, fear of insurance discrimination appears 
to color individuals’ view of pre-symptomatic testing.  
Respondent 5 was a co-parent to an individual who had recently 
passed away from cancer-related issues. The couple had one living daughter, 
age 15, and a son who died at age 6 from cancer related causes. In e-mail 
correspondence, respondent 5 included the following information:   
 
 
 
 
 Throughout the questionnaire, this respondent appeared to be strongly 
in favor of pediatric testing. His P-TAS score was 55, which is the maximum 
value. During the stage of change questionnaire, the individual was still in the 
pre-contemplation stage, but reported that he was committed to obtaining p53 
genetic testing for his daughter and disclosing the results.  
“We have recently been discussing with (child) about getting her tested for 
(LFS)”.  
“We are living with the effects that losing a mother and a brother because 
of (LFS), has on a child. The worries and fears that are created when she is ill 
or just doesn’t feel good. (Child) is constantly worried about developing 
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 This individual brought up an interesting point that many parents most 
likely consider. His 15-year old daughter could potentially have up to a 20% 
risk of cancer before she turns 18. She has seen her younger brother and 
mother suffer from their cancer diagnoses and eventually pass away. This 
child may be experiencing excessive cancer-related anxiety by not knowing 
whether she has the same cancer risks as her mother and brother. If she did 
not inherit the p53 mutation from her mother, then this child has the general 
population cancer risk. The estimated cancer for a female of the general 
population to develop cancer before the age of 20 is 0.32% (Ries, Kosary, 
Hankey, Miller, Clegg & Edwards, 1998). Alternatively, if she did inherit the 
p53 mutation, the complaints and health concerns of this child may be taken 
more seriously.  
 
Strengths of Study 
 As no research has examined parental attitudes towards testing 
children for p53 mutations, this is a pilot study. Other studies have looked at 
parental feelings and beliefs regarding pre-symptomatically testing children 
for other cancer predisposition syndromes such as Familial Adenomatous 
Polyposis (FAP), Von-Hippel Lindau disease (VHL) and Hereditary Breast 
and Ovarian Cancer syndrome (HBOC) (Andrews et al.,2006) (Peshkin et al., 
2009) (Rasmussen et al., 2010). Patenaude et al. (1996) questioned parents 
about their attitudes regarding testing children for a theoretical cancer 
predisposition gene. One of the largest strengths of this study is that it is the 
first to focus specifically on parents whose children are at risk of inheriting 
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p53 mutation and to ascertain parental attitudes toward testing children for 
p53 genetic mutations.  
 Another strength of this study is its use of several validated measures 
in pediatric genetic testing and health-related behavior (Tercyak et al., 
2002),(Andrews et al., 2006),(Peshkin et al., 2009), (Peterson et al.,2009). 
The pediatric testing attitudes scale (P-TAS) has recently been validated and 
is expected to play an integral role in future studies looking at parental 
attitudes towards testing minors for cancer susceptibility (Peshkin et al., 
2009). The communication questionnaire has been used in several studies and 
is shown to be reliable (Terycak et al., 2002, Terycak et al., 2006). The trans-
theoretical model has also been extensively used in health related research 
and is a measure that is believed to accurately measure stage of change and 
decisional balance (Prochaska & Velicer, 1997). Additionally, individuals 
were given the opportunity to provide qualitative responses. We were 
therefore able to collect both qualitative and quantitative responses from most 
respondents. The tools used were appropriate for the study.  
 
Limitations of Study 
The major limitation to the study is our small sample size. Only 6 out of 25 
potentially reachable participants returned the questionnaire, giving a response rate of 
28.57%.  We are unable to draw explicit conclusions about our population given this small 
response rate. In this study, non-response may be attributed to a number of factors. A 
previous study using the same population of participants showed a response rate of near 
70% (Peterson et al., 2008). Surveys were conducted over the telephone, while ours were 
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mailed-out. Past studies have shown that mail-out surveys were more revealing than 
telephone, yet showed a lower response rate (Morrissey, 1995) (Erhart, Wetzel, Krugel & 
Ravens-Sieberer, 2009).  Although telephone reminder calls are believed to strengthen 
response rate (Traina, MacLean, Park & Kahn, 2005), our attempt to do so did not appear 
to be successful.  Due to time constraints, we were not able to conduct the survey over the 
telephone. If we had used the telephone to conduct the survey, it may have been possible to 
probe participants for more qualitative responses, as those appeared to be the most 
revealing in our study. 
Low response rate may also be attributed to the timing of the initial survey 
distribution. Our survey was initially mailed in mid-December, near the winter holidays. 
Two reminder surveys were then mailed out. It is possible that the timing of initial survey 
distribution contributed to the poor response rate. We are therefore unable to generalize our 
results towards a greater population. 
Another potential limitation of the study is that parental attitudes towards testing 
children for cancer predisposition likely have many more factors which we did not inquire 
about. Such factors may be child’s current and past health, health of parent(s) and siblings, 
child’s maturity level and cognitive ability of the child. These are all factors which could 
potentially play a large role in a parent’s decision whether to test their child for a p53 
mutation. 
Conclusion 
 Although clinical genetic testing has been available for Li-Fraumeni 
syndrome, little is known about parental attitudes towards testing children for 
p53 mutations. This is the first study to address this issue. In general, parents 
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seem to be in favor of childrens’ rights to be tested for p53 mutations. 
Although most people appear to agree that children should have the 
opportunity to be tested, they vary in regard to their attitudes towards who 
should be involved in the decision making process and when it should occur. 
While some individuals believe that children should be tested as soon as 
possible, others reported that it should occur later in adolescence or when the 
child reaches the age of majority. Parents also varied in communication with 
their children. Some reported having open discussions about genetic testing 
and general health frequently, while others have reportedly never had these 
conversations. 
 Using the health psychology trans-theoretical model, we ascertained 
the decisional balance and stage of change of each individual. Decisional 
balance appeared to be a reliable predictor of stage of change. Individuals 
who favored the “pros” in decisional balance are either committed to test their 
children for p53 genetic mutations or have already done it. Individuals who 
ranked the “pros” and “cons” more equally appear to be in pre-contemplation 
stage of testing their children. 
 Perhaps most revealing were the qualitative comments that the 
participants provided us. These thoughtful responses highlighted several key 
issues in considerations for pediatric genetic testing including concerns about 
insurance discrimination and pediatric assent to genetic testing.  
 Although our small sample size does not allow us to draw any 
conclusions about our population, individuals provided us with enlightening 
responses. Li-Fraumeni syndrome is clearly a life-altering diagnosis. Parents 
73 
 
considering whether to test their at-risk children for this devastating condition 
do not appear to be taking the decision lightly. There is no straightforward 
answer as to whether children should undergo p53 genetic testing. This and 
future studies addressing this issue may improve communication between 
health care providers and parents about pediatric genetic testing for cancer 
predisposition syndromes. 
 
Future Studies 
 As we limited our study to individuals who have children 27 years of 
age or younger, it may be beneficial to expand the study population to all 
individuals who have a diagnosis of or are at risk of inheriting Li-Fraumeni 
Syndrome. This would likely improve the sample size. Additionally, 
performing a telephone survey would most likely improve the survey 
response and sample size. A telephone survey would also allow us to ask 
probing questions and obtain more qualitative responses. 
 It would be interesting to see how the recently enacted genetic 
information non-discrimination act (GINA) and health care reform will 
change the concerns individuals have regarding insurance discrimination. 
Literature often cites this to be a major deterrent to genetic testing (Patenaude 
et al., 1996), (Veach, Bartels & LeRoy, 2001), (Hall, McEwen & Barton, 
2005). Responses from this study are consistent with those reports. With 
changing regulations on insurance discrimination and an evolving health care 
model, individuals may alter their ideas about this possibility. 
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 Finally, it might be worthwhile to perform a similar study on 
providers who may encounter issues such as pre-symptomatic p53 genetic 
testing. This could be done by identifying providers who care for patients 
who have a family history of Li-Fraumeni syndrome and providing them with 
a similar survey as the one in our study. Comparisons could then be made 
between responses of parents and provider. Results from this study could 
provide insight on differing perceptions between parent and medical 
specialist. 
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Appendix A : Letter of Invitation 
 
Department of Genetics-Unit 209 
Phone: (713) 792-7555 Fax: (713) 794-4421 
<Date> 
 
<Name> 
<Address Line 1> 
<Address Line 2> 
 
Dear Ms/Mr. <Name>: 
I am writing to thank you for your continued participation in our research involving 
Li Fraumeni 
Syndrome (LFS), and to let you know about a new research opportunity. I would like to 
invite you to take part in a research study entitled Attitudes of families with Li-Fraumeni 
Syndrome, a rare hereditary cancer predisposition syndrome towards predictive testing in 
children. We are interested in obtaining information about parental attitudes toward p53 
genetic testing in their children.  
 
We are inviting you because you have participated in our LFS research at M. D. 
Anderson Cancer Center (MDACC). The study will include individuals with a diagnosis or 
those who have family members with a diagnosis of Li-Fraumeni Syndrome. Your 
decision to join this research study is voluntary. You may decline to participate, or choose 
to discontinue participation at any time. Your decision about participation in this study or 
answering questions will not change the care or services that you receive from MDACC. 
Participation in this research study involves completing the enclosed survey 
regarding your feelings toward p53 testing in your child. You or somebody in your family 
has been diagnosed with Li-Fraumeni Syndrome, a cancer predisposition condition. As you 
know, LFS is a rare hereditary condition that increases cancer risk, and is most often 
attributed to genetic changes in the p53 tumor suppressor gene. We have identified a 
mutation, or change in the p53 gene in you or a family member. As you may know, p53 
testing is not routinely performed in minors for a variety of reasons. We are interested in 
learning how you feel about having your child tested for the p53 mutation.  The questions 
that you will be answering will help the researchers and physicians to better understand the 
needs of families with children at risk for LFS and provide the appropriate services.  We 
will ask you questions about how you feel about genetic testing in your children. 
If you agree to participate in this study, please complete the questionnaire that is 
included in this packet and return to us in the pre-addressed envelope.  By consenting to 
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this study, you will give us access to this questionnaire, as well as your MDACC medical 
records.  
 
If you choose to participate in the study, you will be asked to give your 
identification number on the questionnaire. Your identification is: (Kindred number and 
Unique number). This number allows us to determine who has responded to the study.  
 
This questionnaire is also available online. If you prefer to do online survey, please 
notify us at 713-745-3477 and we will send you the instructions.  The online survey 
consists of the same questions as the one that is included in this packet and was created 
using a professional account on Survey Monkey, which is a confidential survey making 
tool.  Your response will be maintained strictly confidential and will only be shared with 
study staff.  
 
Although your participation in this project may not have direct benefit to you, it 
will provide useful information that may advance our understanding of genetic testing.  
Some of the questions on the survey may make you feel uncomfortable. You may decline 
to answer any questions or stop taking the survey at any time. If you decide to participate 
in the study, it is very important that you answer as honestly as you can to the questions 
that are asked. Please complete this survey alone.  
 
If you have any questions or would like more information, please contact Leslie 
Newman at 713-745-3477 or Dr. Strong, MD at (713) 792-7555.  
Thank you very much for considering this invitation to participate in our study. 
 
Sincerely, 
 
 
Leslie Newman, BS      Louise C. Strong, M.D 
   
Graduate School of Biomedical Sciences   Sue and Radcliffe Killam 
Chair 
Email: leslie.a.newman@uth.tmc.edu    Professor of Cancer 
Genetics 
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APPENDIX B: Questionnaire 
 
Instructions: We are interested in learning about your attitudes toward p53 testing for healthy children under the age of 21. As you may 
know, p53 genetic testing for cancer susceptibility has not been routine in healthy minor age children due to several medical, social, and 
psychological reasons, however p53 alterations do affect cancer risk in children, and we wish to learn about your experience and 
attitudes toward such testing. The following questions are directed toward your personal feelings about genetic testing in healthy 
minors.  
Please indicate your agreement with each of the following statements using the scale below. 
 Strongl
y 
Disagr
ee 
Disagr
ee 
Neithe
r 
Agree 
nor 
Disagr
ee 
Agree Strongl
y 
Agree 
1. Children under age 18 should be given the opportunity to be tested 
for the p53 mutation 
1 2 3 4 5 
2. Parents should decide if their children are allowed to have a p53 
test or not, even if a doctor disagrees 
1 2 3 4 5 
3. Even though some of the cancers associated with p53 mutations do 
not affect children until they reach adulthood, children should still be 
offered p53 testing 
1 2 3 4 5 
4. Children should be involved in making the decision about whether 
or not they participate in p53 testing 
1 2 3 4 5 
5. If children are tested and they carry a p53 mutation (that is, they 
test positive), they should be told about their test result immediately 
1 2 3 4 5 
6. Even if there is no known prevention, treatment, or cure for the 
cancers associated with p53 mutations, children should be offered p53 
testing 
1 2 3 4 5 
7. If children are tested and they turn out to carry a p53 mutation (that 
is, they test positive), then this information should be shared with the 
child’s pediatrician 
1 2 3 4 5 
8. I want my child to be tested for a p53 mutation before age 18 1 2 3 4 5 
9. If children are tested and they do not carry a p53 mutation (that is, 
they test negative), they should be told about their test result 
immediately 
1 2 3 4 5 
10. The benefits of children participating in p53 genetic testing 
outweigh the risks 
1 2 3 4 5 
11. I am in favor of p53 gene testing for children 1 2 3 4 5 
CONTINUED ON NEXT PAGE… 
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I am in favor of p53 gene testing for my child if: (Circle One) 
  Yes No Unsure 
12 My child has developed cancer 1 2 3 
11 One of my other children has developed 
cancer  
1 2 3 
12 He/She agrees to have testing 1 2 3 
13 He/She requests testing 1 2 3 
14 He/She is older than ten 1 2 3 
15 If the results would help manage my child’s health 1 2 3 
16 If results would help other family members  1 2 3 
 
 
 
 
 
 
 
 
 
 
 
 
17 At what age do you feel it is appropriate to test an individual 
for a p53 mutation?   
 
79 
 
 
 
 
 
Please complete the following for each of your biological children. 
 
1  Child’s year of birth 2 Is this child 
living? 
3 If No, at what age did the child pass away? 
 
Yes      No  
Age:  
Cause of death: 
4 Gender 5 Have you shared your family’s genetic testing results with this child? 
Male    Female  Yes      No  Not Applicable  
 
The following questions pertain to conversations you may or may not have had with your child about 
their risk of inheriting an alteration in the cancer susceptibility gene, p53, and genetic counseling and 
testing.  
 How often have you:  How comfortable were you with 
this? 
 
 Not at 
all 
Rarely 
Some- 
times 
Often  
Not 
at all 
A 
little 
bit 
Mostl
y Very 
6 
Talked with this child about 
genetic counseling and testing 
for p53? 
1 2 3 4  1 2 3 4 
7 Asked this child how he/she felt about genetic testing? 1 2 3 4  1 2 3 4 
8 Tried to reassure this child that you would be OK? 1 2 3 4  1 2 3 4 
9 Tried to reassure this child that he/she would be OK? 1 2 3 4  1 2 3 4 
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CONTINUED ON NEXT PAGE… 
 
Please indicate the steps you have (or have not) taken regarding seeking genetic testing 
for your child.  
 
 
I have 
no 
interest 
in this 
I 
haven’t 
thought 
about it 
I have 
thought 
about it 
I am 
committed 
to it 
I’ve 
already 
done it 
10 Discussed genetic testing with 
this child 1 2 3 4 5 
11 
Sought information regarding 
testing for a p53 mutation in 
this child 
1 2 3 4 5 
12 Made an appointment with a doctor/genetic counselor 1 2 3 4 5 
13 Met with a doctor/genetic 
counselor 1 2 3 4 5 
14 Had this child tested for a p53 
mutation 1 2 3 4 5 
15 Shared this child’s genetic 
testing results with him or her 1 2 3 4 5 
 
 
 
 
 
CONTINUED ON NEXT PAGE… 
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THE FOLLOWING QUESTIONS (15-19) ARE FOR INDIVIDUALS WHOSE CHILD HAS HAD 
GENETIC TESTING. 
If this child has not had genetic testing, please SKIP TO # 20. 
Please indicate how important you feel each of the following was in your decision to pursue 
genetic testing in this child using the 1-5 point scale. The following list includes reasons some 
people give for wanting to have genetic testing. 
 
 Not 
Important 
Slightly 
Important 
Somewhat 
Important Important 
Very 
Important 
16 
I would have been relieved to 
know that my child did not 
have a p53 mutation 
1 2 3 4 5 
17 
My family’s experience with 
cancer made me more 
concerned about my child’s 
own risk for the disease 
1 2 3 4 5 
18 
My  child could do something 
to lower his/her cancer risk 1 2 3 4 5 
19 
I / My child could plan for the 
future 1 2 3 4 5 
20 
Other (please write) 
 
 
THE FOLLOWING QUESTIONS (20-24) ARE FOR INDIVIDUALS WHOSE CHILD HAS NOT 
HAD GENETIC TESTING. 
If your child has had genetic testing, this portion of the survey is complete. If you have other children 
whom you have not completed the survey for, please do so in the provided forms. If you have completed 
the questionnaire for all of your children, please turn to the last page. 
 
Please indicate how important you feel each of the following would be to you using the 1-5 point 
scale. The following list includes reasons some people give for wanting to have genetic testing.  
  Not 
Important 
Slightly 
Important 
Somewhat 
Important Important 
Very 
Important 
21 
I would be relieved to know 
that my child did not have a 
p53 mutation 
1 2 3 4 5 
22 
My family’s experience with 
cancer makes me more 
concerned about my child’s 
own risk for the disease 
1 2 3 4 5 
23 My  child can do something to lower his/her cancer risk 
1 2 3 4 5 
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24 I / My child can plan for the future 
1 2 3 4 5 
25  Other (please write) 
 
 
 
The following list includes reasons some people give for NOT wanting to have genetic testing. 
Please indicate how important you feel each of the following would be for you using the same 1-
5 point scale. 
  Not 
Important 
Slightly 
Important 
Somewhat 
Important Important 
Very 
Important 
26 I’m afraid I would get too upset 1 2 3 4 5 
27 I’m afraid my child would get too upset 
1 2 3 4 5 
28 
I am concerned that having the 
test might cause problems with 
my child’s insurance 
1 2 3 4 5 
29 There is nothing my child can do 
about getting cancer 
1 2 3 4 5 
30 I am concerned about my family’s reaction 
1 2 3 4 5 
31 I am worried about how it would 
affect my child’s future 
1 2 3 4 5 
32 Other (please write)  
 
 
Thank you for completing this section of the survey. If you have other children whom you have not 
completed the survey for, please do so in the provided forms. If you have completed the questionnaire for all 
of your children, please turn to the last page.  
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The following are questions about YOU. Please complete the following sections.  
 
1  Gender 2 What is your 
marital 
status? 
3 What is the highest grade or level of 
schooling you completed? 
 
Male      Female  
   Single 
  Married 
  Separated 
  Divorced 
  Widowed 
 
  Some high school 
  High school graduate 
  Some college 
  College graduate (4 Year Degree) 
  Associate’s degree 
  Upper-level degree (Masters, PhD, MD) 
4 What is your current 
occupational status? 
5 What is your (combined) annual household income? 
 
 
  Employed (Full Time) 
  Employed (Part Time) 
   Unemployed (Not 
seeking a job) 
   Unemployed (Seeking a 
job) 
  Homemaker 
  Student 
  Retired 
    Less than $25,000 
    $25,000 - $50,000 
    $50,000 - $75,000 
    More than $75,000 
 
Thank you very much for completing this questionnaire. The information you have provided has been very 
helpful and we appreciate your thoughtful answers. 
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Appendix C - Reminder Letter to Non-Responders 
 
Date 
Name 
Address 
Dear 
Over the last several weeks we have tried to contact you at the above address about our 
study Attitudes of families with Li-Fraumeni Syndrome, a rare hereditary cancer 
predisposition syndrome towards predictive testing in children. As of <the date shown at 
the top of this letter>, we have we have not received the questionnaire back from you nor 
have we received a refusal to take part in this study.   
We are interested in obtaining information about parental attitudes toward p53 genetic 
testing in their children.  The questions that you will be answering will help the researchers 
and physicians to better understand the needs of families with children at risk for LFS and 
provide the appropriate services. Participation in the study involves signing an informed 
consent and completing a questionnaire. 
If you are interested in taking part in this study and have lost the informed consent and 
questionnaire, we have enclosed another copy for your convenience.  If you do not wish to 
take part in this part of the study, please indicate this and also return the blank 
questionnaire to us in the pre-addressed envelope.   
We appreciate your participation in the study.  If you have any questions, please contact 
me at your earliest convenience at 713-745-3477 or Dr. Louise Strong at (713) 792-7555.  
Sincerely, 
 
Leslie Newman, BS 
U.T. M.D. Anderson Cancer Center 
1515 Holcombe Blvd., Box 209 
Houston, Texas 77030-4009 
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